• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国三个经济发达城市中耐多药结核病患者面临的挑战

Challenges Faced by Multidrug-Resistant Tuberculosis Patients in Three Financially Affluent Chinese Cities.

作者信息

Zhang Peize, Xu Guanghui, Song Yanhua, Tan Jie, Chen Tao, Deng Guofang

机构信息

Department of Pulmonary Medicine & Tuberculosis, The Third People's Hospital of Shenzhen, Shenzhen, People's Republic of China.

Jiangmen Institute of Tuberculosis Prevention and Control, Guangdong, People's Republic of China.

出版信息

Risk Manag Healthc Policy. 2020 Nov 2;13:2387-2394. doi: 10.2147/RMHP.S275400. eCollection 2020.

DOI:10.2147/RMHP.S275400
PMID:33173363
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7648070/
Abstract

PURPOSE

The aim of this study was to analyze socioeconomic burdens and other difficulties that multidrug-resistant tuberculosis (MDR-TB) patients in cities are facing, to identify major obstacles and which groups of patients are most affected.

METHODS

Face-to-face and phone-call interviews were conducted in early 2018 to follow-up with patients newly diagnosed with MDR-TB in 2017 in three tuberculosis hospitals in three financially affluent Chinese cities. Demographic data and information on their medical care, insurance coverage, and medical expenses were collected and analyzed.

RESULTS

A total of 144 newly diagnosed MDR-TB cases were reviewed during the study period, excluding 38 who were lost to follow-up and 29 patients who refused to participate, 77 patients were enrolled in this study. A total of 61 (79%) of these patients were hospitalized after MDR-TB diagnosis with an average hospital stay of 14 days, of them 57 (74%) were sputum positive on diagnosis. The proportion of patients who failed community care were 48% married, 56% in white collar employment and 43% in temp jobs/unemployed. In terms of insurance coverage, the proportion of patients who failed community care were 23% with no insurance and/or New Rural Co-operative Medical Care Scheme (NRCMS) and 45% with Urban Employee Basic Medical Insurance (UEBMI)/Urban Residents Basic Medical Insurance (URBMI) and commercial insurance. Difficulties patients encountered were, financial pressure (33%), psychological stress (26%), adverse drug reactions (23%), repulsive reaction to injections (17%). Fourty-eight percent of the patients spent over ¥2000 (USD300) per month on TB treatment.

CONCLUSION

Despite insurance coverage, financial hardship remains the number one difficulty MDR-TB patients encountered in relatively financially affluent cities. Among them, the married working class were found to be the most financially sensitive group and have the highest tendency to fail community care. It is of utmost urgency to enhance the current medical policy to improve treatment adherence.

摘要

目的

本研究旨在分析城市耐多药结核病(MDR-TB)患者所面临的社会经济负担及其他困难,以确定主要障碍以及受影响最严重的患者群体。

方法

2018年初进行了面对面和电话访谈,对中国三个经济发达城市的三家结核病医院2017年新诊断的MDR-TB患者进行随访。收集并分析了人口统计学数据以及他们的医疗护理、保险覆盖范围和医疗费用等信息。

结果

研究期间共审查了144例新诊断的MDR-TB病例,排除38例失访者和29例拒绝参与者后,77例患者纳入本研究。这些患者中共有61例(79%)在MDR-TB诊断后住院,平均住院时间为14天,其中57例(74%)诊断时痰菌阳性。社区护理失败的患者中,48%已婚,56%为白领职业,43%为临时工作/失业。在保险覆盖方面,社区护理失败的患者中,23%没有保险和/或新型农村合作医疗(NRCMS),45%有城镇职工基本医疗保险(UEBMI)/城镇居民基本医疗保险(URBMI)和商业保险。患者遇到的困难有,经济压力(33%)、心理压力(26%)、药物不良反应(23%)、对注射的排斥反应(17%)。48%的患者每月用于结核病治疗的费用超过2000元(300美元)。

结论

尽管有保险覆盖,但在经济相对发达的城市,经济困难仍然是MDR-TB患者遇到的首要困难。其中,已婚工人阶级被发现是对经济最敏感的群体,社区护理失败的倾向最高。加强现行医疗政策以提高治疗依从性迫在眉睫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ec/7648070/4adc32ad313a/RMHP-13-2387-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ec/7648070/58eb2ba775a4/RMHP-13-2387-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ec/7648070/a73fd0553eaf/RMHP-13-2387-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ec/7648070/4adc32ad313a/RMHP-13-2387-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ec/7648070/58eb2ba775a4/RMHP-13-2387-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ec/7648070/a73fd0553eaf/RMHP-13-2387-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ec/7648070/4adc32ad313a/RMHP-13-2387-g0003.jpg

相似文献

1
Challenges Faced by Multidrug-Resistant Tuberculosis Patients in Three Financially Affluent Chinese Cities.中国三个经济发达城市中耐多药结核病患者面临的挑战
Risk Manag Healthc Policy. 2020 Nov 2;13:2387-2394. doi: 10.2147/RMHP.S275400. eCollection 2020.
2
Tuberculosis结核病
3
Disparity in reimbursement for tuberculosis care among different health insurance schemes: evidence from three counties in central China.不同医疗保险计划下结核病治疗报销的差异:来自中国中部三个县的证据。
Infect Dis Poverty. 2016 Jan 27;5:7. doi: 10.1186/s40249-016-0102-4.
4
Cost effectiveness of decentralised care model for managing MDR-TB in India.印度采用分散式护理模式管理耐多药结核病的成本效益。
Indian J Tuberc. 2018 Jul;65(3):208-217. doi: 10.1016/j.ijtb.2017.08.031. Epub 2017 Sep 28.
5
Innovative social protection mechanism for alleviating catastrophic expenses on multidrug-resistant tuberculosis patients in Chhattisgarh, India.印度恰蒂斯加尔邦减轻耐多药结核病患者灾难性费用的创新社会保护机制。
WHO South East Asia J Public Health. 2015 Jan-Jun;4(1):69-77. doi: 10.4103/2224-3151.206624.
6
Multi-source financing for tuberculosis treatment in China: key issues and challenges.中国结核病治疗的多源融资:关键问题与挑战
Infect Dis Poverty. 2021 Mar 10;10(1):17. doi: 10.1186/s40249-021-00809-4.
7
Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China.经济障碍与应对策略:对中国云南耐多药结核病及结核病医疗服务可及性的定性研究
BMC Public Health. 2017 Feb 22;17(1):221. doi: 10.1186/s12889-017-4089-y.
8
Factors associated with catastrophic total costs due to tuberculosis under a designated hospital service model: a cross-sectional study in China.指定医院服务模式下导致结核病灾难性总费用的相关因素:中国的一项横断面研究。
BMC Public Health. 2020 Jun 26;20(1):1009. doi: 10.1186/s12889-020-09136-z.
9
Disparities in end-of-life care, expenditures, and place of death by health insurance among cancer patients in China: a population-based, retrospective study.中国癌症患者的医疗保险在临终关怀、支出和死亡地点方面的差异:一项基于人群的回顾性研究。
BMC Public Health. 2020 Sep 4;20(1):1354. doi: 10.1186/s12889-020-09463-1.
10
Analysis of multi drug resistant tuberculosis (MDR-TB) financial protection policy: MDR-TB health insurance schemes, in Chhattisgarh state, India.耐多药结核病(MDR-TB)财务保护政策分析:印度恰蒂斯加尔邦的耐多药结核病医疗保险计划
Health Econ Rev. 2018 Jan 27;8(1):3. doi: 10.1186/s13561-018-0187-5.

引用本文的文献

1
Trends of drug-resistant tuberculosis and risk factors to poor treatment-outcome: a database analysis in Littoral region-Cameroon, 2013-2022.耐多药结核病趋势及不良治疗结局的危险因素:喀麦隆滨海地区 2013-2022 年数据库分析。
BMC Public Health. 2024 Nov 18;24(1):3195. doi: 10.1186/s12889-024-20585-8.
2
The trial of sending short message service multidrug-resistant tuberculosis patients in Indonesia: the chance to increase knowledge and motivation.印度尼西亚针对耐多药结核病患者发送短信服务的试验:增加知识和动力的契机。
J Public Health Afr. 2023 Dec 1;14(12):2675. doi: 10.4081/jphia.2023.2675. eCollection 2023 Dec 27.
3

本文引用的文献

1
An Overview of Tuberculosis-Designated Hospitals in China, 2009-2015: A Longitudinal Analysis of National Survey Data.中国结核病定点医院概况:2009-2015 年全国调查数据分析
Biomed Res Int. 2019 Aug 20;2019:9310917. doi: 10.1155/2019/9310917. eCollection 2019.
2
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素:一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
3
Infectious Diseases Continued to be the World's Core Challenge.
Predictors and Trends of MDR/RR-TB in Shenzhen China: A Retrospective 2012-2020 Period Analysis.
中国深圳耐多药/利福平耐药结核病的预测因素及趋势:2012 - 2020年回顾性分析
Infect Drug Resist. 2021 Oct 27;14:4481-4491. doi: 10.2147/IDR.S335329. eCollection 2021.
4
Factors Associated with Medical Follow-Up Adherence for Patients on All-Oral Regimen for Multidrug-Resistant Tuberculosis in Shenzhen, China.中国深圳耐多药结核病全口服治疗方案患者医疗随访依从性的相关因素
Patient Prefer Adherence. 2021 Jul 5;15:1491-1496. doi: 10.2147/PPA.S316253. eCollection 2021.
5
Prevalence of primary anti-tuberculosis drug resistance at the tertiary center in Saudi Arabia and associated risk factors.沙特阿拉伯三级中心原发性抗结核药物耐药率及相关危险因素分析。
Saudi Med J. 2021 Jul;42(7):728-734. doi: 10.15537/smj.2021.42.7.20200797.
传染病仍然是全球的核心挑战。
Ethiop J Health Sci. 2017 Nov;27(6):570. doi: 10.4314/ejhs.v27i6.1.
4
Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China.中国接受标准化二线治疗方案的耐多药结核病患者的临床结局。
J Infect. 2018 Apr;76(4):348-353. doi: 10.1016/j.jinf.2017.12.017. Epub 2018 Feb 7.
5
Survey on Tuberculosis Patients in Rural Areas in China: Tracing the Role of Stigma in Psychological Distress.中国农村地区肺结核患者调查:探寻耻辱感在心理困扰中的作用。
Int J Environ Res Public Health. 2017 Oct 4;14(10):1171. doi: 10.3390/ijerph14101171.
6
Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.耐多药结核病患者不良治疗结局的预测因素:一项回顾性队列研究。
Clin Microbiol Infect. 2018 Jun;24(6):612-617. doi: 10.1016/j.cmi.2017.09.012. Epub 2017 Sep 29.
7
The role of health system governance in strengthening the rural health insurance system in China.健康体系治理在中国农村健康保险体系中的作用。
Int J Equity Health. 2017 May 23;16(1):44. doi: 10.1186/s12939-017-0542-x.
8
An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.抗多药耐药结核病治疗的更新系统评价和荟萃分析。
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.00803-2016. Print 2017 Mar.
9
Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China.经济障碍与应对策略:对中国云南耐多药结核病及结核病医疗服务可及性的定性研究
BMC Public Health. 2017 Feb 22;17(1):221. doi: 10.1186/s12889-017-4089-y.
10
Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation.中国上海耐多药结核分枝杆菌的传播:一项使用全基因组测序和流行病学调查的回顾性观察研究
Lancet Infect Dis. 2017 Mar;17(3):275-284. doi: 10.1016/S1473-3099(16)30418-2. Epub 2016 Dec 3.